Open AccessImmune Response Persistence and Safety of a Booster Dose of the Tetravalent Dengue Vaccine in Adolescents and Adults Who Previously Completed the 3-dose Schedule 4–5 Years Earlier in Latin America
Author(s) -
Diana Coronel,
Enid J García-Rivera,
Doris Maribel Rivera,
José Luis Arredondo-Garcı́a,
Reynaldo Dietze,
Ana Paula Perroud,
Margarita Cortés,
Matthew Bonaparte,
Hao Wang,
Anke Pag,
Frédérique Jantet-Blaudez,
Luis Andrey Rojas Peñalosa,
Gustavo H. Dayan,
Betzana Zambrano,
Carlos A. DiazGranados,
Fernando Noriega
Publication year - 2020
Publication title -
the pediatric infectious disease journal/the pediatric infectious disease journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.028
H-Index - 140
eISSN - 1532-0987
pISSN - 0891-3668
DOI - 10.1097/inf.0000000000002830
Subject(s) - dengue vaccine , medicine , dengue fever , booster dose , booster (rocketry) , plaque reduction neutralization test , dengue virus , immunology , vaccination , neutralizing antibody , immune system , virology , immunization , physics , astronomy
We previously described an increased immune response 28 days after a booster dose of the live, attenuated, tetravalent dengue vaccine (CYD-TDV) in healthy adolescents and adults in Latin America (CYD64, NCT02623725). This follow-up study evaluated immune response persistence and safety of a CYD-TDV booster dose up to Month (M) 24 post-booster.